N/A
N=278
Clinical Follow-up of Anti-Carbamylated Antibody Status in Rheumatoid Arthritis
RheumatoId Arthritis
Bottom Line
View on ClinicalTrials.gov: NCT02958319 ↗Enrolled (actual)
278
Serious AEs
0.0%
Results posted
Jan 2022
Primary outcome: Primary: DAS28-ESR — 3.75; 3.72; 3.59; 3.69 units on a scale — p=0.82
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Universidad Autonoma de Nuevo Leon
- Primary completion
- Nov 2018
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY DAS28-ESR |
3.75; 3.72; 3.59; 3.69; 3.65; 3.77 | 0.82 |
Summary
Patients with rheumatoid arthritis (RA) with positive antibodies against carbamylated proteins (anti-CarP) have a more severe clinical course. The primary objective of this study in adult subject with RA is as follows: To explore the clinical differences in activity indexes (Disease Activity Score of 28 joints with Erythro Sedimentaion Rate (DAS28-ESR)) at 6, 12 and 18 months of follow up according the anti-CarP antibodies status.
Eligibility Criteria
Inclusion Criteria
- Rheumatoid arthritis patients according to ACR EULAR 2010 classification that accepted and signed informed consent
Exclusion Criteria
- Chronic kidney disease and pregnant patients
Data sourced from ClinicalTrials.gov (NCT02958319). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.